New Antibody-Drug conjugate enters human trials for advanced cancers
NCT ID NCT06823167
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check safety and find the right dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IM-1021 (an antibody-drug conjugate)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced cancers that have not responded to other therapies.
- What could go wrong
- This is an early Phase 1 trial with only 117 participants, so the main goal is safety and dosing—not yet proving effectiveness. Side effects are unknown and could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brown University
RECRUITINGProvidence, Rhode Island, 02903, United States
-
Centre Leon-Berard
RECRUITINGLyon, 69008, France
-
City Of Hope
RECRUITINGDuarte, California, 91010, United States
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
-
Copenhagen University Hospital
RECRUITINGCopenhagen, DK-2100, Denmark
-
Emory Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
-
Gabrail Cancer Center
RECRUITINGCanton, Ohio, 44718, United States
-
Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
LITO, Institut Curie Hospital Gropu
RECRUITINGParis, 75005, France
-
Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
NEXT Oncology
RECRUITINGIrving, Texas, 75039, United States
-
Norton Cancer Institute
RECRUITINGLouisville, Kentucky, 40202, United States
-
START - Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Sarah Cannon Research Institute - Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
UT San Antonio Mays Cancer
RECRUITINGSan Antonio, Texas, 78229, United States
-
University of California
RECRUITINGLos Angeles, California, 90095, United States
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
University of Nebraska Medical Center
RECRUITINGOmaha, Nebraska, 68105, United States
-
Yale University Medical Center
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the key to better CAR-T therapy lie in the gut?
- Can a new nucleotide analogue boost cancer treatment?
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can a drug duo tame Triple-Negative breast cancer?
- Can a custom mRNA vaccine keep ovarian cancer from coming back?
- Can a cancer pill keep working outside the lab? a Real-World test begins